In summary, subgroup analysis found that the association between high serum IGF-I and increased risk of prostate cancer was more prominent in studies published in the past decade and in NCC designs, but heterogeneity increased with the expansion of sample size and research background. The gene discussed is IGF1; the disease is Familial prostate cancer.